Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04662580 · ClinicalTrials.gov registry record · Phase 1
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
A Phase 1 study of Metastatic Prostate Cancer, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 183
- Enrollment target
- 12
- Study locations
NCT04662580 is a Phase 1 study of Metastatic Prostate Cancer that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 183 participants, roughly in line with the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target. The trial reports 12 study locations across 10 states.
The verdict
NCT04662580, a Phase 1 study of Metastatic Prostate Cancer, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 183 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
Conditions Studied
Interventions
- DRUG Apalutamide
- DRUG Prednisone
- DRUG Abiraterone acetate
- DRUG ARX517
Study Locations (12)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California, Los Angeles School of Medicine - Los Angeles
- UCSF Medical Center at Mission Bay - San Francisco
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Missouri
- Washington University St. Louis School Medicine Siteman Cancer Center - St Louis
Nebraska
- GU Research Network - Omaha
New York
- Weill Cornell Medical College - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04662580
The ClinicalTrials.gov registry entry for NCT04662580 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Apalutamide is the first listed.
NCT04662580 reports 12 study locations spanning 10 distinct geographic areas - top geographies include California, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT04662580 about?
NCT04662580 is a clinical study titled "ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer". This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
What is the current status of trial NCT04662580?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2021-05-03. Estimated completion is 2026-12-31.
What conditions does trial NCT04662580 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer.
What interventions are being tested in trial NCT04662580?
The interventions under investigation include: Apalutamide (DRUG), Prednisone (DRUG), Abiraterone acetate (DRUG), ARX517 (DRUG).
Who is sponsoring clinical trial NCT04662580?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04662580 being conducted?
This trial has 12 study locations across California, Georgia, Indiana, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AZD0754 in Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
RECRUITING · Phase 1
-
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
RECRUITING · Phase 1
-
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.